<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Singla A</submitter><funding>Division of Chemistry</funding><funding>National Institute of Allergy and Infectious Diseases</funding><funding>NIAID NIH HHS</funding><funding>Men of Distinction</funding><pagination>40724-40737</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9480101</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(36)</volume><pubmed_abstract>&lt;i>Pseudomonas aeruginosa&lt;/i> is the leading nosocomial and community-acquired pathogen causing a plethora of acute and chronic infections. The Centers for Disease Control and Prevention has designated multidrug-resistant isolates of &lt;i>P. aeruginosa&lt;/i> as a serious threat. A novel delivery vehicle capable of specifically targeting  &lt;i>P. aeruginosa&lt;/i>, and encapsulating antimicrobials, may address the challenges associated with these infections. We have developed hetero-multivalent targeted liposomes functionalized with host cell glycans to increase the delivery of antibiotics to the site of infection. Previously, we have demonstrated that compared with monovalent liposomes, these hetero-multivalent liposomes bind with higher affinity to &lt;i>P. aeruginosa&lt;/i>. Here, compared with nontarg</pubmed_abstract><journal>ACS applied materials &amp; interfaces</journal><pubmed_title>Hetero-Multivalent Targeted Liposomal Drug Delivery to Treat &lt;i>Pseudomonas aeruginosa&lt;/i> Infections.</pubmed_title><pmcid>PMC9480101</pmcid><funding_grant_id>CHE-1904784</funding_grant_id><funding_grant_id>R03AI139650</funding_grant_id><funding_grant_id>R21 AI149383</funding_grant_id><funding_grant_id>R21AI149383</funding_grant_id><funding_grant_id>R03 AI139650</funding_grant_id><pubmed_authors>Chirra B</pubmed_authors><pubmed_authors>Cannon CL</pubmed_authors><pubmed_authors>Chen Q</pubmed_authors><pubmed_authors>Hassan AM</pubmed_authors><pubmed_authors>Shah KN</pubmed_authors><pubmed_authors>Singla A</pubmed_authors><pubmed_authors>Southerland MR</pubmed_authors><pubmed_authors>Chapman MJ</pubmed_authors><pubmed_authors>Rose RE</pubmed_authors><pubmed_authors>Gairola A</pubmed_authors><pubmed_authors>Simbassa SB</pubmed_authors><pubmed_authors>Ivanov I</pubmed_authors><pubmed_authors>Wu HJ</pubmed_authors><pubmed_authors>Sen A</pubmed_authors><pubmed_authors>Baeza J</pubmed_authors><pubmed_authors>Basharat A</pubmed_authors><pubmed_authors>Raina R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Hetero-Multivalent Targeted Liposomal Drug Delivery to Treat &lt;i>Pseudomonas aeruginosa&lt;/i> Infections.</name><description>&lt;i>Pseudomonas aeruginosa&lt;/i> is the leading nosocomial and community-acquired pathogen causing a plethora of acute and chronic infections. The Centers for Disease Control and Prevention has designated multidrug-resistant isolates of &lt;i>P. aeruginosa&lt;/i> as a serious threat. A novel delivery vehicle capable of specifically targeting  &lt;i>P. aeruginosa&lt;/i>, and encapsulating antimicrobials, may address the challenges associated with these infections. We have developed hetero-multivalent targeted liposomes functionalized with host cell glycans to increase the delivery of antibiotics to the site of infection. Previously, we have demonstrated that compared with monovalent liposomes, these hetero-multivalent liposomes bind with higher affinity to &lt;i>P. aeruginosa&lt;/i>. Here, compared with nontarg</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Sep</publication><modification>2025-04-04T20:07:50.873Z</modification><creation>2025-04-04T20:07:50.873Z</creation></dates><accession>S-EPMC9480101</accession><cross_references><pubmed>36018830</pubmed><doi>10.1021/acsami.2c12943</doi></cross_references></HashMap>